Close Menu

The Drying Pipeline

Both AstraZeneca and Novartis announced that drugs they had for depression and hypertension that were in the late stages of development have failed, reports Bloomberg, adding that AstraZeneca's drugs turned out to be disappointing while Novartis's tests on Tekturna were halted due to safety concerns. Further, Sanofi's multiple sclerosis drug, Aubagio, has not performed better than an older therapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.